Twist Bioscience Insider Sale: CFO Sells 918 Shares; Holding 102,917

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reporting person Adam Laponis, Chief Financial Officer, filed a Form 4 disclosing a non-discretionary sale of 918 shares of common stock on 08/21/2025 at a reported price of $25.964 per share. The filing states these shares were sold to satisfy tax withholding obligations associated with the vesting of restricted stock units under the companys equity plans, described as a mandatory "sell to cover" and not a discretionary trade.

Following the transaction, the reporting person beneficially owns 102,917 shares, which includes shares purchased under the companys Employee Stock Purchase Plan as noted in the filing. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Laponis and contains explanatory notes clarifying the nature of the sale and the ESPP exemption.

Insights

Corporate Governance Expert

TL;DR: Routine, non-discretionary sell-to-cover of RSU taxes by the CFO; no indication of insider-driven market-timing.

The Form 4 discloses a standard post-vesting sell-to-cover of 918 shares at $25.964 per share to satisfy tax withholding obligations. The filing explicitly states the sale was mandated by the issuer's equity plan, which supports the affirmative defense under Rule 10b5-1 for planned transactions when applicable. The reporting person retains a substantial direct stake of 102,917 shares, and the filing notes ESPP-acquired shares that were exempt under Rule 16b-3 provisions. From a governance perspective, this is a routine compliance disclosure with no red flags such as unexplained discretionary trades or sudden large disposals.

Securities Analyst

TL;DR: Small, tax-related disposition by the CFO; immaterial to company capitalization or control.

The reported disposition of 918 shares represents a minor, administrative sale tied to RSU vesting rather than an expression of view on company prospects. At the reported price of $25.964, the transaction value is modest relative to the reported retained holding of 102,917 shares. The disclosure also confirms participation in the ESPP, with those purchases treated as exempt in the filing. This transaction should not materially affect investor valuation metrics or signal management-level liquidity pressure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laponis Adam

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		S		918(1)	D	$25.964	102,917(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

2. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did TWST CFO Adam Laponis disclose on the Form 4?

The filing discloses a sale of 918 shares on 08/21/2025 at $25.964 per share to satisfy tax withholding for vested restricted stock units.

Was the sale by the insider discretionary or mandatory?

The filing states the sale was a mandated "sell to cover" required by the issuers equity plans and does not represent a discretionary trade by the reporting person.

How many TWST shares does the reporting person own after the transaction?

After the transaction the reporting person beneficially owns 102,917 shares, per the Form 4.

Does the Form 4 note any Employee Stock Purchase Plan (ESPP) activity?

Yes. The filing indicates included shares were acquired under the issuers ESPP and that those shares were exempt under applicable Rule 16b-3 provisions.

Who signed the Form 4 for Adam Laponis?

The Form 4 was signed by Kendra Fox as Attorney-in-Fact for Adam Laponis on 08/25/2025.